For active ankylosing spondylitis (AS) in adult TNFi-IR patients1
For active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adult TNFi-IR patients1
US-MULT-230356
US-MULT-230356
For active ankylosing spondylitis (AS) in adult TNFi-IR patients1
For active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adult TNFi-IR patients1
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor
Payers cover RINVOQ after the trial of 
with >95% preferred commercial coverage2,*,†
Preferred coverage also could
mean a STANDARD PRIOR
AUTHORIZATION (PA) and
APPEALS PROCESS,
potential for one-time
PA/appeal approval.
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
‡Percentages reflect anticipated coverage.
TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Commercial plan preferred formulary status for TIM therapies for active AS under the pharmacy benefit as of June 20232
Cimzia is a product available on medical benefit plans.7
Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.
The products listed here are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Products listed here are not interchangeable with one another. Not all products are shown, including biosimilars. Material differences exist between the listed products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.
Please see HUMIRA full Prescribing Information.
Preferred coverage also could
mean a STANDARD PRIOR
AUTHORIZATION (PA) and
APPEALS PROCESS,
potential for one-time
PA/appeal approval.
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Commercial plan preferred formulary status for TIM therapies for active nr-axSpA under the pharmacy benefit as of June 20232
Cimzia is a product available on medical benefit plans.7
Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.
The products listed here are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Products listed here are not interchangeable with one another. Not all products are shown, including biosimilars. Material differences exist between the listed products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.
Please see HUMIRA full Prescribing Information.
Payers cover RINVOQ after the trial of with >95% preferred medicare part d coverage2,*,†
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
‡Percentages reflect anticipated coverage.
TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Medicare Part D plan preferred formulary status for TIM therapies for active AS under the pharmacy benefit as of June 20232
Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.
The products listed here are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Products listed here are not interchangeable with one another. Not all products are shown, including biosimilars. Material differences exist between the listed products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.
Please see HUMIRA full Prescribing Information.
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Medicare Part D plan preferred formulary status for TIM therapies for active nr-axSpA under the pharmacy benefit as of June 20232
Cimzia is a product available on medical benefit plans.7
Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.
The products listed here are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Products listed here are not interchangeable with one another. Not all products are shown, including biosimilars. Material differences exist between the listed products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.
Please see HUMIRA full Prescribing Information.
Empower and educate patients
Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete
Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:
Insurance support when needed
Help with access & treatment affordability
Complete can help your commercial patients save:
Empowering Patients
Nurse Ambassadors, In Their Own Words
*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
†Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) or HUMIRA® (adalimumab) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com for RINVOQ® patients and HUMIRASavingsCard.com for HUMIRA® patients, or call 1.800.2RINVOQ or 1.800.4HUMIRA for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie
‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
To enroll a patient in RINVOQ Complete:
Download the enrollment & prescription form for your specialty.
Fill out the form with your patient
Fax the form to 1-678-727-0690
Inform your patient that they have been enrolled
*Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
†Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment‑related questions, including further referrals.
Track treatment
The Complete App is designed to help patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:
Streamline the Rx process
CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.
With CompletePro.com, you can:
Register now at
Download RINVOQ resources to support your
patients and your practice.
Review the safety profile of RINVOQ,
including both short- and long-term analyses
RINVOQ is indicated for the treatment of:
Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis or Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine.
REFERENCES
